Journal of Clinical Oncology, Vol 21, Issue 7
(April), 2003: 1326-1331
© 2003 American Society for Clinical Oncology
Role of Sentinel Lymphadenectomy in Thin Invasive Cutaneous Melanomas
Richard J. Bleicher,
Richard Essner,
Leland J. Foshag,
Leslie A. Wanek,
Donald L. Morton
From the John Wayne Cancer Institute at Saint John’s Health Center, Santa Monica, CA.
Address reprint requests to Richard Essner, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA; email: essnerr{at}jwci.org.
Purpose: Regional lymph node status is the strongest prognostic determinant in early-stage melanoma. Lymphatic mapping and sentinel lymphadenectomy (LM/SL) is standard to stage regional nodes because it is accurate and minimally morbid, yet its role for thin ( 1.5 mm) primary melanomas is unknown.
Patients and Methods: Our melanoma database of more than 10,000 patients was reviewed for patients with melanomas 1.50 mm thick who underwent LM/SL. All had lymphoscintigrams and LM/SL via dye alone or with radiopharmaceutical. Patients with tumor-positive sentinel nodes (SNs) underwent completion dissections.
Results: Five hundred twelve patients underwent LM/SL. Most were men (57%), and median age was 49 years. Most primary melanomas were on the torso (44%). Twenty-five patients (4.9%) had tumor-positive SNs. The thinnest lesion with a nodal metastasis was 0.35 mm. The SN-negative and SN-positive cohorts were equivalent by sex, but SN+ patients tended to be younger (P = .053), with significantly more SN metastases in those younger than 44 years (P = .005). No consistent pathology among SN-positive primary melanomas was found. Among those with 1.01- to 1.05-mm primaries, 7.1% were SN-positive. Among 272 patients with lesions 1.00 mm, 2.9% had positive SNs and 1.7% with lesions 0.75 mm had SN metastases. All 13 deaths were in SN-negative patients. Median follow-up durations in SN-positive and SN-negative patients were 25 and 45 months, respectively.
Conclusion: The high nodal positivity rate associated with primary melanomas 1.01 to 1.50 mm thick suggests that LM/SL is indicated in this group. Younger age may be correlated with nodal metastases in patients with lesions 1.00 mm. Lesions 0.75 mm have minimal metastatic potential, and therefore LM/SL is rarely indicated.
Supported by grant no. CA29605 from the National Cancer Institute and Saban Family Foundation.
Presented at the Thirty-Eighth Annual Meeting of the American Society of Clinical Oncology, May 18–21, 2002, Orlando, FL.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
B. E. Wright, R. P. Scheri, X. Ye, M. B. Faries, R. R. Turner, R. Essner, and D. L. Morton
Importance of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma
Arch Surg,
September 1, 2008;
143(9):
892 - 900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. K. Sondak and J. L. Messina
Lymphangiogenesis: Host and Tumor Factors in Nodal Metastasis
Arch Dermatol,
April 1, 2008;
144(4):
536 - 537.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I. Ross
Early-stage melanoma: staging criteria and prognostic modeling.
Clin. Cancer Res.,
April 1, 2006;
12(7):
2312s - 2319s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tsao, M. B. Atkins, and A. J. Sober
Management of Cutaneous Melanoma
N. Engl. J. Med.,
September 2, 2004;
351(10):
998 - 1012.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Johnson, C. R. Bradford, S. B. Gruber, V. K. Sondak, and J. L. Schwartz
Staging Workup, Sentinel Node Biopsy, and Follow-up Tests for Melanoma: Update of Current Concepts
Arch Dermatol,
January 1, 2004;
140(1):
107 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
